France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical ...

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical ...

Futures on Wall Street have begun trading on Sunday evening US time on a negative note amidst rising uncertainties on trade ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company ...